Pyridine-3-Sulfonyl Chloride CAS 16133-25-8 Purity ≥98.5% (GC) Vonoprazan Fumarat Intermediate Factory

Chemical Name: Pyridine-3-Sulfonyl Chloride  CAS: 16133-25-8 Purity: ≥98.5% (GC) Appearance: Colorless or Pale Yellow Liquid Intermediate of Vonoprazan Fumarate (CAS: 1260141-27-2) High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, 25kg/Barrel, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Supply Vonoprazan Fumarate and Related Intermediate 5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde CAS 881674-56-2 Pyridine-3-Sulfonyl Chloride CAS 16133-25-8 Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2
Item Specifications
Appearance Colorless or Pale Yellow Liquid 
Purity / Analysis Method ≥98.5% (GC)
Boiling Point 110.0~112.0℃/2mm Hg
Single Impurity ≤0.50%
Total Impurities ≤1.5%
Test Standard Enterprise Standard
Usage Intermediate of Vonoprazan Fumarate (CAS: 1260141-27-2)

Description:

Specifications:

Package & Storage:

Chemical Name Pyridine-3-Sulfonyl Chloride
Synonyms 3-Pyridinesulfonyl Chloride; 3-Pyridylsulfonyl Chloride; m-Pyridinesulfonyl Chloride; Piperidine-3-Sulfonylchloride
CAS Number 16133-25-8
CAT Number RF-PI540
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C5H4ClNO2S
Molecular Weight 177.61
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Pyridine-3-Sulfonyl Chloride (CAS: 16133-25-8) is an intermediate of Vonoprazan Fumarate (CAS: 1260141-27-2). Vonoprazan Fumarate, discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours